Avadel Pharmaceuticals PLC (NASDAQ:AVDL)’s share price hit a new 52-week low during trading on Monday . The company traded as low as $1.15 and last traded at $1.18, with a volume of 1500 shares traded. The stock had previously closed at $1.29.
A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, January 7th. ValuEngine raised shares of Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. LADENBURG THALM/SH SH downgraded shares of Avadel Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, February 8th. Finally, Laidlaw set a $2.00 target price on shares of Avadel Pharmaceuticals and gave the stock a “hold” rating in a research note on Monday, March 18th. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $5.08.
The company has a debt-to-equity ratio of 41.63, a quick ratio of 3.13 and a current ratio of 3.25. The company has a market capitalization of $48.85 million, a P/E ratio of -0.60 and a beta of 1.78.
Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its earnings results on Friday, March 15th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. Avadel Pharmaceuticals had a negative net margin of 92.29% and a negative return on equity of 126.79%. The company had revenue of $20.92 million for the quarter. On average, analysts predict that Avadel Pharmaceuticals PLC will post -1.39 EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of the business. Brandes Investment Partners LP increased its position in shares of Avadel Pharmaceuticals by 12.4% during the fourth quarter. Brandes Investment Partners LP now owns 7,119,054 shares of the company’s stock valued at $18,367,000 after acquiring an additional 783,506 shares during the last quarter. Broadfin Capital LLC increased its position in shares of Avadel Pharmaceuticals by 11.1% during the fourth quarter. Broadfin Capital LLC now owns 3,102,673 shares of the company’s stock valued at $8,005,000 after acquiring an additional 309,900 shares during the last quarter. Morgan Stanley increased its position in shares of Avadel Pharmaceuticals by 61.2% during the third quarter. Morgan Stanley now owns 777,272 shares of the company’s stock valued at $3,412,000 after acquiring an additional 295,036 shares during the last quarter. Fosun International Ltd acquired a new stake in shares of Avadel Pharmaceuticals during the fourth quarter valued at about $826,000. Finally, Highbridge Capital Management LLC acquired a new stake in shares of Avadel Pharmaceuticals during the fourth quarter valued at about $253,000. 53.43% of the stock is currently owned by institutional investors.
WARNING: “Avadel Pharmaceuticals (AVDL) Hits New 52-Week Low at $1.15” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2019/04/15/avadel-pharmaceuticals-avdl-hits-new-52-week-low-at-1-15.html.
Avadel Pharmaceuticals Company Profile (NASDAQ:AVDL)
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.
Featured Story: What is Net Asset Value (NAV)?
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.